ES2536791T3 - Administración de vectores lentivirales al cerebro - Google Patents

Administración de vectores lentivirales al cerebro Download PDF

Info

Publication number
ES2536791T3
ES2536791T3 ES11727743.4T ES11727743T ES2536791T3 ES 2536791 T3 ES2536791 T3 ES 2536791T3 ES 11727743 T ES11727743 T ES 11727743T ES 2536791 T3 ES2536791 T3 ES 2536791T3
Authority
ES
Spain
Prior art keywords
vev
protein
administration
vector
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11727743.4T
Other languages
English (en)
Inventor
Peter Widdowson
Scott Ralph
Kyriacos Mitrophanous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1009052.0A external-priority patent/GB201009052D0/en
Priority claimed from GBGB1100502.2A external-priority patent/GB201100502D0/en
Priority claimed from GBGB1107184.2A external-priority patent/GB201107184D0/en
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Application granted granted Critical
Publication of ES2536791T3 publication Critical patent/ES2536791T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un vector lentiviral para la administración al putamen para su uso en el tratamiento de una afección neurológica, en el que una composición que comprende el vector lentiviral se administra directamente al putamen por infusión continua usando una cánula y en el que se administran entre 10-600 &mul de la composición de vector por tramo a una velocidad de flujo de al menos 2 μl/min, y en el que el vector lentiviral se administra usando una cánula con una perforación equivalente o más estrecha de aproximadamente 28 de calibre.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
5
15
25
35
45
55
65 E11727743
12-05-2015
CD4. Pero si el gen env en estos vectores se ha sustituido con secuencias de env de otros virus de ARN, entonces puede tener un espectro infeccioso más amplio (Verma y Somia (1997) Nature 389(6648):239-242). A modo de ejemplo, Miller et al. pseudotiparon un vector MoMLV con la envuelta del retrovirus anfotrópico 4070A (Mol. Cell. Biol. 5:431-437), otros colaboradores han pseudotipado un vector lentiviral basado en el VIH con la glucoproteína del VEV (Verma y Somia (1997) Nature 389(6648):239-242).
En otra alternativa, la proteína Env puede ser una proteína Env modificada tal como una proteína Env mutante o manipulada. Las modificaciones pueden hacerse o seleccionarse para introducir la capacidad de elección de diana o para reducir la toxicidad o para otro fin (Marin et al. (1996) J Virol 70(5):2957-2962; Nilson et al. (1996) Gene Ther 3(4):280-286; y Fielding et al. (1998) Blood 91(5):1802-1809 y referencias citadas en su interior).
El vector puede pseudotiparse, por ejemplo, con un gen que codifica al menos parte de la proteína G de la rabia o la proteína VEV-G.
VEV-G:
La proteína de la envuelta (G) del virus de la estomatitis vesicular (VEV), un rabdovirus, es una proteína de la envuelta que se ha mostrado que es capaz de pseudotipar ciertos retrovirus que incluyen lentivirus.
Su capacidad para pseudotipar vectores retrovirales basados en MoMLV en ausencia de cualquier retroproteína de la envuelta vírica se mostró por primera vez por Emi y col. (1991) J. Virol. 65:1202-1207. El documento WO 94/294440 enseña que los vectores retrovirales pueden pseudotiparse satisfactoriamente con VEV-G. Estos vectores de VEV-G pseudotipados pueden usarse para transducir una amplia variedad de células de mamífero. Más recientemente, Abe et al. (1998) J. Virol 72(8): 6356-6361 enseñan que las partículas retrovirales no infecciosas pueden hacerse infecciosas mediante la adición de VEV-G.
Burns et al. (1993) Proc. Natl. Acad. Sci. USA 90:8033-8037 pseudotiparon satisfactoriamente el retrovirus VLM con VEV-G y esto produjo un vector que tenía un intervalo de huéspedes alterado en comparación con el VLM en su forma nativa. Se ha mostrado que los vectores pseudotipados con VEV-G infectan no solo células de mamífero, sino también líneas celulares derivadas de peces, reptiles e insectos (Burns et al. (1993) Proc. Natl. Acad. Sci. USA 90:8033-8037). También han mostrado que es más eficaz que las envueltas anfotrópicas tradicionales para una variedad de líneas celulares (Yee y col. (1994) Proc. Natl. Acad. Sci. USA 91:9564-9568 y Emi et al. (1991) J. Virol. 65:1202-1207). La proteína del VEV-G también puede usarse para pseudotipar ciertos lentivirus y retrovirus debido a que su cola citoplásmica puede interaccionar con los núcleos retrovirales.
La provisión de una envuelta de pseudotipado no lentiviral tal como la proteína VEV-G proporciona la ventaja de que las partículas de vector pueden concentrarse a un alto título sin pérdida de infectividad (Akkina et al. (1996) J. Virol. 70:2581-2585). Las proteínas de la envuelta de lentivirus y retrovirus son evidentemente incapaces de resistir a las fuerzas de cizallamiento durante la ultracentrifugación, probablemente debido a que consisten en dos subunidades no covalentemente ligadas. La interacción entre las subunidades puede romperse por la centrifugación. En comparación, la glucoproteína del VEV está compuesta por una única unidad. Por tanto, el pseudotipado de la proteína del VEV-G puede ofrecer posibles ventajas.
El documento WO 00/52188 describe la generación de vectores retrovirales y lentivirales pseudotipados, de líneas celulares productoras estables, que tienen la proteína G del virus de la estomatitis vesicular (VEV-G) como proteína de la envuelta viral asociada a la membrana, y proporciona una secuencia de gen para la proteína del VEV-G.
Virus del río Ross
Se ha usado la envuelta viral del río Ross para pseudotipar un vector lentiviral no de primate (VIF) y tras la administración sistémica transdujo predominantemente el hígado (Kang et al. (2002) J Virol 76(18):9378-9388). Se informó que la eficiencia era 20 veces superior a la obtenida con el vector pseudotipado por VEV-G, y provocó menos citotoxicidad como se mide por niveles en suero de enzimas del hígado sugerentes de hepatotoxicidad.
El virus del río Ross (VRR) es un alfavirus propagado por mosquitos que es endémico y epidémico en regiones tropicales y templadas de Australia. Las tasas de anticuerpo en las poblaciones normales en la zona costera templada tienden a ser bajas (6 % al 15 %), aunque la sero-prevalencia alcanza del 27 al 37 % en las planicies del sistema del río del valle de Murray. De 1979 a 1980, el virus del río Ross se volvió endémico en las islas del Pacífico. La enfermedad no es contagiosa entre seres humanos y nunca es mortal, siendo el primer síntoma el dolor de articulaciones con fatiga y letargo en aproximadamente la mitad de los pacientes (Fields Virology, quinta edición (2007) Eds. Knipe y Howley. Lippincott Williams and Wilkins).
Baculovirus GP64
Se ha mostrado que la proteína del baculovirus GP64 es una alternativa atractiva a VEV-G para vectores virales usados en la producción a gran escala del virus de título alto requerido para aplicaciones clínicas y comerciales
7
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15

Claims (1)

  1. imagen1
ES11727743.4T 2010-05-28 2011-05-27 Administración de vectores lentivirales al cerebro Active ES2536791T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB201009052 2010-05-28
GBGB1009052.0A GB201009052D0 (en) 2010-05-28 2010-05-28 Vector
GBGB1100502.2A GB201100502D0 (en) 2011-01-12 2011-01-12 Vector
GB201100502 2011-01-12
GB201107184 2011-04-28
GBGB1107184.2A GB201107184D0 (en) 2011-04-28 2011-04-28 Vector
PCT/GB2011/051009 WO2011148194A1 (en) 2010-05-28 2011-05-27 Delivery of lentiviral vectors to the brain

Publications (1)

Publication Number Publication Date
ES2536791T3 true ES2536791T3 (es) 2015-05-28

Family

ID=45003388

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11727743.4T Active ES2536791T3 (es) 2010-05-28 2011-05-27 Administración de vectores lentivirales al cerebro

Country Status (7)

Country Link
US (2) US20110293571A1 (es)
EP (1) EP2575894B1 (es)
JP (1) JP5965392B2 (es)
CN (1) CN102946907A (es)
DK (1) DK2575894T3 (es)
ES (1) ES2536791T3 (es)
WO (1) WO2011148194A1 (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
GB201118636D0 (en) * 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
RU2721275C2 (ru) 2012-12-12 2020-05-18 Те Брод Инститьют, Инк. Доставка, конструирование и оптимизация систем, способов и композиций для манипуляции с последовательностями и применения в терапии
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
CN113425857A (zh) 2013-06-17 2021-09-24 布罗德研究所有限公司 用于肝靶向和治疗的crispr-cas系统、载体和组合物的递送与用途
AU2014281030B2 (en) 2013-06-17 2020-07-09 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
WO2014204729A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2932436A1 (en) 2013-12-12 2015-06-18 The Broad Institute, Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
AU2014361784A1 (en) 2013-12-12 2016-06-23 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
EP4219699A1 (en) 2013-12-12 2023-08-02 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
SG10201804976YA (en) 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Genome Editing
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
ES2780904T3 (es) 2014-08-17 2020-08-27 Broad Inst Inc Edición genómica usando nickasas Cas9
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
US20170247762A1 (en) 2014-10-27 2017-08-31 The Board Institute Inc. Compositions, methods and use of synthetic lethal screening
EP3230452A1 (en) 2014-12-12 2017-10-18 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016094867A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
WO2016100974A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
AU2015369725A1 (en) 2014-12-24 2017-06-29 Massachusetts Institute Of Technology CRISPR having or associated with destabilization domains
US20180271891A1 (en) 2015-03-11 2018-09-27 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
US10835585B2 (en) 2015-05-20 2020-11-17 The Broad Institute, Inc. Shared neoantigens
EP3822291A1 (en) 2015-06-10 2021-05-19 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CA3012631A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
RU2021120582A (ru) 2015-06-18 2021-09-02 Те Брод Инститьют, Инк. Мутации фермента crispr, уменьшающие нецелевые эффекты
EP3436575A1 (en) 2015-06-18 2019-02-06 The Broad Institute Inc. Novel crispr enzymes and systems
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
EP3319631A4 (en) 2015-07-08 2019-01-09 American Gene Technologies International Inc. HIV PREMUNICATION AND IMMUNOTHERAPY
US11214800B2 (en) 2015-08-18 2022-01-04 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CA3024543A1 (en) 2015-10-22 2017-04-27 The Broad Institute, Inc. Type vi-b crispr enzymes and systems
US11492670B2 (en) 2015-10-27 2022-11-08 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
WO2017106657A1 (en) 2015-12-18 2017-06-22 The Broad Institute Inc. Novel crispr enzymes and systems
IL310925A (en) 2016-01-15 2024-04-01 American Gene Tech Int Inc Methods and preparations for activating GAMMA-DELTA T cells
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
EP4036231A1 (en) 2016-03-09 2022-08-03 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
EP3445848A1 (en) 2016-04-19 2019-02-27 The Broad Institute, Inc. Novel crispr enzymes and systems
AU2017253107B2 (en) 2016-04-19 2023-07-20 Massachusetts Institute Of Technology CPF1 complexes with reduced indel activity
US20200263190A1 (en) 2016-04-19 2020-08-20 The Broad Institute, Inc. Novel crispr enzymes and systems
CA3024494A1 (en) 2016-05-10 2017-11-16 United States Government As Represented By The Department Of Veterans Affairs Lentiviral delivery of crispr/cas constructs that cleave genes essential for hiv-1 infection and replication
US11976292B2 (en) 2016-06-08 2024-05-07 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
CA3028158A1 (en) 2016-06-17 2017-12-21 The Broad Institute, Inc. Type vi crispr orthologs and systems
US20210222164A1 (en) 2016-06-29 2021-07-22 The Broad Institute, Inc. Crispr-cas systems having destabilization domain
CA3028982A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018035388A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
AU2017342555A1 (en) 2016-10-14 2019-05-30 Children's Medical Center Corporation Compositions and methods for treating diseases and disorders of the central nervous system
WO2018136435A1 (en) 2017-01-17 2018-07-26 Children's Medical Center Corporation Compositions and methods for treating lysosomal storage diseases and disorders
WO2018136434A1 (en) 2017-01-17 2018-07-26 Children's Medical Center Corporation Compositions and methods for diagnosing and treating peroxisomal diseases
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP2020505074A (ja) 2017-01-30 2020-02-20 カー・ヴェー・エス ザート エス・エー ウント コー． カー・ゲー・アー・アーＫＷＳ ＳＡＡＴ ＳＥ ＆ Ｃｏ． ＫＧａＡ ゲノム工学のためのエンドヌクレアーゼに対する修復鋳型の結合
JP7370861B2 (ja) 2017-02-12 2023-10-30 ビオンテック ユーエス インコーポレイテッド Ｈｌａに基づく方法および組成物ならびにそれらの使用
US11739308B2 (en) 2017-03-15 2023-08-29 The Broad Institute, Inc. Cas13b orthologues CRISPR enzymes and systems
CA3057142A1 (en) 2017-04-03 2018-10-11 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
BR112019021378A2 (pt) 2017-04-12 2020-05-05 Massachusetts Inst Technology ortólogos de crispr tipo vi inovadores e sistemas
US20200405639A1 (en) 2017-04-14 2020-12-31 The Broad Institute, Inc. Novel delivery of large payloads
WO2018204777A2 (en) 2017-05-05 2018-11-08 The Broad Institute, Inc. Methods for identification and modification of lncrna associated with target genotypes and phenotypes
CN111511388A (zh) 2017-09-21 2020-08-07 博德研究所 用于靶向核酸编辑的系统、方法和组合物
US20200255828A1 (en) 2017-10-04 2020-08-13 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US11547614B2 (en) 2017-10-31 2023-01-10 The Broad Institute, Inc. Methods and compositions for studying cell evolution
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
EP3833761A1 (en) 2018-08-07 2021-06-16 The Broad Institute, Inc. Novel cas12b enzymes and systems
US20210317429A1 (en) 2018-08-20 2021-10-14 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
EP3876952A4 (en) 2018-11-05 2022-08-24 American Gene Technologies International Inc. VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA
US11384344B2 (en) 2018-12-17 2022-07-12 The Broad Institute, Inc. CRISPR-associated transposase systems and methods of use thereof
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CN113474840A (zh) 2018-12-21 2021-10-01 百欧恩泰美国公司 用于预测hla ii类特异性表位及表征cd4+ t细胞的方法和系统
WO2020183374A1 (en) * 2019-03-10 2020-09-17 Axovant Sciences Gmbh Gene therapy compositions and methods for treating parkinson's disease
US20220177863A1 (en) 2019-03-18 2022-06-09 The Broad Institute, Inc. Type vii crispr proteins and systems
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
CA3150747A1 (en) 2019-08-16 2021-02-25 Massachusetts Institute Of Technology Targeted trans-splicing using crispr/cas13
WO2021067611A2 (en) * 2019-10-01 2021-04-08 Children's Medical Center Corporation Compositions and methods for treating alzheimer's disease
KR20230142704A (ko) 2020-12-14 2023-10-11 바이오엔테크 유에스 인크. 암 면역요법을 위한 조직 특이적 항원
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
NZ334860A (en) 1996-10-17 2001-02-23 Oxford Biomedica Ltd Retroviral vectors with one or more auxiliary genes vpr, vif, tat and nef to be absent; with evidence that if all auxiliary genes absent the transduction efficiency is greatest
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US6815431B2 (en) * 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
CA2328491A1 (en) 1998-05-22 1999-12-02 Oxford Biomedica (Uk) Limited Retroviral delivery system
US6506378B1 (en) * 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
GB9904905D0 (en) 1999-03-03 1999-04-28 Oxford Biomedica Ltd Cells
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
JP2004511843A (ja) 2000-09-29 2004-04-15 スーパーマーケッツ・オンライン・インコーポレイテッド 引き換えられた消費者のプロモーションの監査証跡をリアルタイムで提供する方法、システム、コンピュータプログラム製品
GB0024550D0 (es) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US6800281B2 (en) * 2000-11-09 2004-10-05 Oxford Biomedica (Uk) Limited Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases
SE0302509D0 (sv) 2003-09-19 2003-09-19 Amersham Biosciences Ab Matrix for separation of polyethers and method of separation
US20060129126A1 (en) 2004-11-19 2006-06-15 Kaplitt Michael G Infusion device and method for infusing material into the brain of a patient
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
WO2008100930A2 (en) 2007-02-13 2008-08-21 Cornell University Convection enhanced delivery apparatus, method and application
US10065021B2 (en) 2007-05-17 2018-09-04 Medgenesis Therapeutix, Inc. Convection-enhanced delivery catheter with removable stiffening member and method for using same
GB0802634D0 (en) 2008-02-13 2008-03-19 Renishaw Plc Catheter
US20100324127A1 (en) * 2008-01-16 2010-12-23 Kay Denis G Treating neurodegenerative diseases with progranulin
WO2009105690A2 (en) * 2008-02-21 2009-08-27 Targeted Genetics Corporation Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
CN102076866A (zh) * 2008-05-29 2011-05-25 利兰·斯坦福青年大学托管委员会 光学控制第二信使的细胞系、系统和方法
CN102124115B (zh) 2008-06-18 2020-03-03 牛津生物医学（英国）有限公司 病毒纯化
US20110214195A1 (en) * 2008-11-10 2011-09-01 The Regents Of The University Of Colorado, A Body Corporate Methods For Treating Clinical Conditions Associated With Lipoprotein Lipase Activity
US20110269826A1 (en) * 2008-11-11 2011-11-03 Oxford Biomedica (Uk) Limited Method

Also Published As

Publication number Publication date
JP5965392B2 (ja) 2016-08-03
JP2013530152A (ja) 2013-07-25
DK2575894T3 (en) 2015-05-26
EP2575894B1 (en) 2015-02-25
US20130281975A1 (en) 2013-10-24
US9339512B2 (en) 2016-05-17
CN102946907A (zh) 2013-02-27
US20110293571A1 (en) 2011-12-01
WO2011148194A1 (en) 2011-12-01
EP2575894A1 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
ES2536791T3 (es) Administración de vectores lentivirales al cerebro
CN105705645B (zh) 逆转录病毒载体
US10829785B2 (en) Nucleic acid application primers
US9969984B2 (en) Storage stable recombinant lentiviral vector preparation
CN102438658A (zh) 非整合型逆转录病毒载体疫苗
Munis Gene therapy applications of non-human lentiviral vectors
Dissen et al. In vivo manipulation of gene expression in non-human primates using lentiviral vectors as delivery vehicles
Kim et al. Stability of retroviral vectors against ultracentrifugation is determined by the viral internal core and envelope proteins used for pseudotyping
ES2561060T3 (es) Transferencia génica en citoblastos epiteliales de las vías respiratorias mediante el uso de vectores de lentivíricos pseudotipados con una proteína espina de virus de ARN
US20240076690A1 (en) Viral vectors and uses thereof
JP2018183165A (ja) レンチウイルスパッケージ化のための非サブタイプｂのｇａｇタンパク質の使用
Miyanohara Preparation of vesicular stomatitis virus-G (VSV-G) conjugate and its use in gene transfer
ES2634144T3 (es) Vectores de transferencia lentivíricos defectuosos que no se integran para vacunas
JP6629210B2 (ja) エンベロープウイルスの産生方法
EP2814952A1 (en) Materials and methods relating to packaging cell lines
Bischof et al. Flexibility in cell targeting by pseudotyping lentiviral vectors
Sachdeva et al. Chimeric HIV‐1 and HIV‐2 lentiviral vectors with added safety insurance
JP2022533766A (ja) レトロウイルス科ウイルスベクターのシュードタイピングのための修飾エンベロープ糖タンパク質およびその取得方法
Morris et al. Characterization of human immunodeficiency virus (HIV)-2 vector mobilization by HIV-1
WO2023125823A1 (zh) 靶向HIV的siRNA和shRNA及其相应的组合、表达盒、细胞及其应用
US8309071B2 (en) Foamy viral envelope genes
RU2478711C1 (ru) Способ повышения эффективности вирусной трансдукции
Markusic et al. 727. Baculovirus GP64 Pseudotyped Lentiviral Vectors for Improved Hepatocyte Transduction
Naka et al. 726. Ultrasound enhances retroviral-mediated gene transfer
Munis Envelope glycoproteins of vesiculoviruses: characteristics of antibody interactions and immunogenicity